Zacks Research Brokers Reduce Earnings Estimates for Bruker

Bruker Co. (NASDAQ:BRKR) – Analysts at Zacks Research reduced their Q3 2025 earnings per share estimates for Bruker in a report released on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.72 per share for the quarter, down from their prior forecast of $0.94. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.96 EPS.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 EPS.

Several other analysts have also weighed in on BRKR. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Citigroup reduced their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Barclays lowered their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Finally, TD Cowen lowered their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.36.

Bruker Stock Up 1.5 %

Shares of NASDAQ:BRKR opened at $58.38 on Thursday. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The business’s 50-day moving average is $61.18 and its 200-day moving average is $64.29. The company has a market capitalization of $8.85 billion, a price-to-earnings ratio of 28.07, a P/E/G ratio of 3.95 and a beta of 1.20.

Hedge Funds Weigh In On Bruker

Several institutional investors have recently added to or reduced their stakes in BRKR. Atria Investments Inc bought a new stake in Bruker in the first quarter worth about $1,142,000. Point72 Asset Management L.P. bought a new stake in shares of Bruker in the 2nd quarter worth approximately $36,472,000. Assenagon Asset Management S.A. lifted its stake in Bruker by 1,694.4% in the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock valued at $12,936,000 after purchasing an additional 191,435 shares during the last quarter. Federated Hermes Inc. grew its holdings in Bruker by 5.3% during the second quarter. Federated Hermes Inc. now owns 166,561 shares of the medical research company’s stock valued at $10,628,000 after purchasing an additional 8,346 shares during the period. Finally, Envestnet Asset Management Inc. grew its holdings in Bruker by 48.5% during the second quarter. Envestnet Asset Management Inc. now owns 301,251 shares of the medical research company’s stock valued at $19,223,000 after purchasing an additional 98,427 shares during the period. Institutional investors own 79.52% of the company’s stock.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien bought 100,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 28.30% of the company’s stock.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. Bruker’s dividend payout ratio (DPR) is currently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.